|
|
Latest oncology clinical development updates
Thursday, January 22, 2026
|
|
|
|
|
OTW News Highlights this week
|
|
|
|
|
|
|
|
|
The supplemental application is principally based on NEOTORCH (NCT04158440), a randomized, double-blind, placebo-controlled phase 3 clinical study aiming to compare the efficacy and safety of toripalimab or placebo in combination with chemotherapy as perioperative treatment for resectable stage II/III NSCLC patients. Led by principal investigator Professor Shun LU of Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, the …
|
|
|
|
|
|
|
|
“Building on our established leadership in metastatic TNBC, this positive opinion reinforces our commitment to the breast cancer community,” said Mika Kakefuda Derynck, MD, Senior Vice President, Clinical Development, Oncology at Gilead Sciences. “People with metastatic TNBC desperately need new options as early as possible. This positive opinion, coupled with the recent EMA approval of Trodelvy monotherapy, is an important …
|
|
|
|
|
|
|
|
“We are excited to announce positive initial data from the first two patients treated with RAD204 in the third dosing cohort, which showed favorable tolerability and tumor reduction in target lesions, with both patients remaining on treatment,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “Importantly, the first patient has achieved a durable confirmed RECIST Partial Response lasting …
|
|
|
|
|
|
|
|
Genmab A/S and AbbVie provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody®-CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, compared with investigator's choice of chemoimmunotherapy (CIT) of either rituximab plus gemcitabine plus oxaliplatin (R-GemOx) or bendamustine plus rituximab (BR) in adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) …
|
|
|
|
|
|
|
|
"mRNA-4200 represents our third off-the-shelf cancer antigen therapy candidate and builds on our efforts to explore broad applicability across multiple cancer types," said David Berman, M.D., Ph.D., Chief Development Officer of Moderna. "By encoding multiple shared tumor targets, this investigational therapy reflects our ongoing efforts to expand the potential of cancer immunotherapy beyond single-target approaches as we continue working to …
|
|
|
|
|
|
|
|
“This collaboration marks an important first step in exploring the broader potential of our PH1 payload technology to combine in unique ways with current classes of ADC payloads across the field to advance ADC innovation and impact,” said Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. “Whitehawk brings a differentiated ADC platform and strong expertise in evaluating novel …
|
|
|
|
|
|
|
|
"The integration of different therapeutic modalities into a single platform has become an important trend in drug development, as exemplified by antibody-drug conjugates (ADCs)," said Lee Kun-woo, CEO of BreezeBio. "By combining small molecules, mRNA, and targeted delivery technologies, we aim to expand BreezeBio's platform into the field of oncology."
|
|
|
|
|
|
Author
Managing Editors
Social Media Managers
|
|
|
|
|
|
Disclaimer: The OTW team take care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is a part of RLS Consultants, which is a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.
|
|
|
|
|
|
|
